Home › Melanoma › Oregon › Beaverton
Melanoma clinical trials in Beaverton, OR
3 studies for Melanoma are looking for participants at sites in and around Beaverton (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- Providence Newberg Medical Center, Newberg · 15 mi away
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Providence Newberg Medical Center, Newberg · 15 mi away
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RecruitingPhase 2
- Providence Newberg Medical Center, Newberg · 15 mi away
About Melanoma
Melanoma is the most serious type of skin cancer. Most have a black or black-blue area. Learn the 'ABCDE' of what to watch for and treatment options.
More about Melanoma on MedlinePlus
Melanoma trials in other cities
- Houston, TX61 studies
- New York City, NY41 studies
- Nashville, TN34 studies
- Los Angeles, CA34 studies
- Pittsburgh, PA31 studies
- Boston, MA25 studies
- St. Louis, MO23 studies
- Durham, NC22 studies
- Philadelphia, PA22 studies
- Tampa, FL21 studies
- Columbus, OH21 studies
- Dallas, TX21 studies
Other studies in Beaverton
- Non-Small Cell Lung Cancer8 studies
- Lung Cancer8 studies
- Breast Cancer6 studies
- Ovarian Cancer5 studies
- Prostate Cancer5 studies
- Colorectal Cancer5 studies
- Bladder Cancer4 studies
- Endometrial Cancer4 studies
- Cancer (all types)3 studies
- Acute Myeloid Leukemia3 studies
- Kidney Cancer (Renal Cell Carcinoma)3 studies
- Urothelial (Transitional Cell) Carcinoma3 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.